←
Victoria Kronsten127 posts
Victoria Kronsten avatar

Victoria Kronsten

@vtkronsten

Academic Clinical Fellow in Hepatology, KCH, PhD student at KCL. BASL Trainee Subcommittee South East Rep, BASL SoMe Working Group member.

◷ Joined November 2020▧ 1 Photos and videos
Frontline Gastro avatar
⟳ Victoria Kronsten retweeted
Frontline Gastro@FrontGastro_BMJ·9 Sep 2025

🔥 New insights on Autoimmune Hepatitis (AIH) treatment! 🔬 From personalized thiopurine therapy 💊 to mycophenolate mofetil (MMF) as a 1st-line option, and advanced biologics like infliximab & rituximab 🌟—discover strategies to tackle difficult-to-treat AIH and improve patient outcomes. 🩺💡 Read the full paper by @MichaelHenegha in @FrontGastro_BMJ 📚 here -> fg.bmj.com/content/early/202… #Livertwitter #AutoimmuneHepatitis #AIH #LiverHealth #PersonalizedMedicine #Biologics #Gastroenterology #MedicalResearch @BASLedu @BritSocGastro @EASLnews @EASLedu @AASLDtweets @PhilSmithIsBack @dr_aditi_kumar @OTavabie @DrJMKennedy @DunnePdj @TrevorTabone @eathar_s @IrenePerezMD @KGananandan @zare_benjamin @medicalreg @dtleiberman

Post attachment
The Roger Williams Institute of Liver Studies avatar
⟳ Victoria Kronsten retweeted
The Roger Williams Institute of Liver Studies@Inst_of_Liver·9 Sep 2025

Last week, clinical teams from across the UK recruiting to the PROMISE trial came together at King's to share insights and learnings. They were joined by patient representatives who shared their stories and experiences of being part of the trial. Speaking of the day, Chief Investigator of the trial @DebbieShawcros1 said: "It was an absolute privilege to bring together colleagues and patients from our 20 clinical sites across the UK to share our experiences and knowledge of being part of the PROMISE Trial. It was particularly humbling to hear the personal experiences of our patients enrolled on the trial and to hear the benefits of participating in clinical research tackling the complications of liver disease." bit.ly/4mbb7Dx

Post attachment
BASL avatar
⟳ Victoria Kronsten retweeted
BASL@basl_events·14 May 2025

Don’t miss the Rare Liver Disease Masterclass! 15–16 June 2025 | London Hear from international experts on Wilson’s Disease, cholestatic liver disorders, alpha-1 antitrypsin deficiency, clinical trials & more. 🔗 Full programme : bit.ly/MasterclassProgramme2… – register now!

Post attachment
Dr Jonny Blackwell avatar
⟳ Victoria Kronsten retweeted
Dr Jonny Blackwell@JonnyBlackwell·22 Feb 2025

This was my absolute highlight of #ECCO2025 So glad I stayed late to hear the big reveal. Low emulsifier diets will change clinical and patient’s lives. Massive congratulations @ProfWhelan & @AaronBancil

Excited to announce results of our #ADDapt trial After 6 years and the help of 154 people with #CrohnsDisease we prove that restricting #emulsifiers improves disease Award winning presentation from @AaronBancil at #ECCO25 Excited for next steps to help people with Crohns

Post attachmentPost attachmentPost attachmentPost attachment
Mussarat Rahim avatar
⟳ Victoria Kronsten retweeted
Mussarat Rahim@MussaratRahim·11 Feb 2025

Very proud to have this published! Thank you to the Lancet and it’s incredible editorial team for your collaboration on this project. Some important updates, hope you find it useful! Appendix has lots of information about pregnancy in AIH, PBC, PSC and Wilson’s too. @MichaelHenegha8 @cathwilliamson5 @TheBileDoc @joostphdrenth @STGHepatology @arjybargy

Physiological changes that occur in pregnancy can exacerbate or improve some pre-existent liver diseases. A new Review describes the challenges of diagnosing, risk stratifying, and managing liver disease in pregnancy: hubs.li/Q035Ld2h0

Post attachment
ELISA POSE avatar
⟳ Victoria Kronsten retweeted
ELISA POSE@PoseElisa·6 Feb 2025

❌💊 Simvastatin + rifaximin does not prevent ACLF development in decompensated cirrhosis ⏳10 years of work in the books 💪🏼 @salvatore_piano @Zac_MD @KGananandan @UschnerFrank @JonelTrebicka @ruben_hernaez @JuanAbraldes @JordiGratacos8 @dewitkoos @EASLnews @AASLDtweets

JAMA@JAMA_current5 Feb 2025

In this clinical trial, addition of simvastatin plus rifaximin to standard therapy did not improve outcomes in patients with decompensated liver cirrhosis. ja.ma/3CGXxqB

Post attachment